ArticleMolecular psychiatry2026
Inhibiting fear memory recall-induced oligodendrogenesis rescues PTSD-like behaviors.
Article in Molecular psychiatry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent re-experiencing traumatic memory is known as a common symptom in post-traumatic stress disorder (PTSD) patients, and its severity is closely related to the progression and prognosis of PTSD. Notably, some individuals with PTSD exhibit white matter abnormalities. Myelin constitutes a critical structure within white matter, and myelination in the adult brain has been demonstrated to actively regulate the consolidation of remote memories. However, the dynamics of myelin after re-experiencing traumatic stressors and their functional significance remain largely unexplored. Here, we developed a repeated fear recall mouse model to mimic re-experiencing symptoms in PTSD patients, and found that repeated fear recall can reinforce remote fear memory while cause anxiety-like behaviors and social preference deficits. This coincides with region-specific oligodendrogenesis, heightened reactivation of fear recall-associated engram cells, and an increase in dendritic spine density, demonstrated through cell-lineage tracing and labeling. We hypothesize that oligodendrogenesis driven by repeated fear recall is sufficient to regulate remote fear memory and behavioral abnormalities. Loss-of-function experiments, either inducing apoptosis of new oligodendrocytes (OLs) or cell-type-specific knocking out (cKO) oligodendroglial transcription factor 2 (Olig2), significantly attenuated the abnormal reinforcement of remote fear memory and ameliorated social deficits induced by repeated fear recall. Moreover, inhibiting oligodendrogenesis through Olig2 cKO relieved anxiety-like behavior. Notably, diminished newly formed OLs also decreases fear recall-induced neuronal activation and dendritic spine density in fear-related brain regions. More importantly, administering rapamycin, a potent inhibitor of oligodendrogenesis, during repeated fear recalls phenocopies the effects of anti-myelination on fear memory-related behavioral defects. In summary, our findings demonstrate that oligodendrogenesis induced by repeated fear recall is sufficient to drive the progression of PTSD-like behaviors, likely by modulating neuronal activity and dendritic spine density within the adult fear circuitry. Pharmacological treatments that inhibiting oligodendrogenesis during the recall phase represent a promising therapeutic strategy for preventing the pathological reinforcement of long-term fear memories, thereby averting the emergence of anxiety-like behaviors and social preference deficits in individuals with PTSD. Schematic image summarizing the major findings of the present study.
Indexed as
Identifiers
42304067What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.